APA (7th ed.) Citation

M, S., A, F., KA, T., F, F., H, R., O, K., . . . Z, B. (2025). HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: Real-world data in patients with primary HER2-amplified breast cancer. Virchows Archiv : an international journal of pathology, 487(5), 1015. https://doi.org/10.1007/s00428-025-04203-5

Chicago Style (17th ed.) Citation

M, Stolz, et al. "HER2/CEP17 ratio Predicts Residual Cancer Burden After Neoadjuvant Dual HER2 Blockade: Real-world Data in Patients with Primary HER2-amplified Breast Cancer." Virchows Archiv : An International Journal of Pathology 487, no. 5 (2025): 1015. https://doi.org/10.1007/s00428-025-04203-5.

MLA (9th ed.) Citation

M, Stolz, et al. "HER2/CEP17 ratio Predicts Residual Cancer Burden After Neoadjuvant Dual HER2 Blockade: Real-world Data in Patients with Primary HER2-amplified Breast Cancer." Virchows Archiv : An International Journal of Pathology, vol. 487, no. 5, 2025, p. 1015, https://doi.org/10.1007/s00428-025-04203-5.